|
gptkbp:instance_of
|
gptkb:depression
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
N06 AX05
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Desyrel
gptkb:Oleptro
gptkb:Trazorel
gptkb:Trazodone
|
|
gptkbp:casnumber
|
79350-36-6
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C19 H22 Cl N5 O
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
MAO inhibitors
hypersensitivity to trazodone
|
|
gptkbp:developed_by
|
gptkb:W._R._Grace_and_Company
|
|
gptkbp:discovered_by
|
gptkb:1961
|
|
gptkbp:dosage_form
|
150 to 600 mg per day
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
extended-release tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trazodone hydrochloride
|
|
gptkbp:interacts_with
|
gptkb:beer
CNS depressants
antihypertensives
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:lifespan
|
5 to 9 hours
|
|
gptkbp:mechanism_of_action
|
serotonin antagonist and reuptake inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_areas
|
sleep medicine
clinical psychology
psychiatry
neuropharmacology
psychopharmacology
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
drowsiness
constipation
dry mouth
weight gain
blurred vision
sexual dysfunction
|
|
gptkbp:used_for
|
gptkb:depression
anxiety
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Trazodone
|
|
gptkbp:bfsLayer
|
6
|